ESMO Asia 2019 takes place in Singapore from November 22th to 24th.
In the following conference, the results of clinical trials related to Rivoceranib (Apatinib) will be announced.
National Cancer Center of Beijing tested the efficacy and safety of Rivoceranib in 20 patients with head and neck adenocarcinoma who failed a primary chemotherapy.
301 military hospital in Beijing tested the efficacy and safety of Rivoceranib + SHR-1210 (anti PD-1 antibody) in 12 patients with advanced lung squamous carcinoma as a primary treatment (analyzed 7 patients).
Fudan University in Shanghai tested the efficacy and safety of Rivoceranib in 40 patients with recurrens-metastatic esophageal cancer who failed a primary chemotherapy.
Diseases Drug type Subject ORR DCR mPFS mOS
Head and neck cancer Apatinib 20 patients 25% 95% 7.5 months 11.0 months
Lung cancer (squamous cell) Apatinib + Camrelizumab 7 patients 85.7% 100%
Esophagus cancer Apatinib 40 patients 12.5% 65% 113 days 158 days
The results of clinical trials on patients with head and neck cancer, lung cancer, and esophagus cancer showed potential for new therapies because of their high efficacy and sufficient manageable side effects.